Cargando…

Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p

BACKGROUND: The chemotherapy drug doxorubicin (Dox) is widely used for treating a variety of cancers. However, its high cardiotoxicity hampered its clinical use. Exosomes derived from stem cells showed a therapeutic effect against Dox-induced cardiomyopathy (DIC). Previous studies reported that exos...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Lei, Xia, Wenzheng, Chen, Didi, Ye, Yijia, Hu, Tingting, Li, Shiting, Hou, Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603694/
https://www.ncbi.nlm.nih.gov/pubmed/33129330
http://dx.doi.org/10.1186/s12951-020-00716-0
_version_ 1783603980544245760
author Zhuang, Lei
Xia, Wenzheng
Chen, Didi
Ye, Yijia
Hu, Tingting
Li, Shiting
Hou, Meng
author_facet Zhuang, Lei
Xia, Wenzheng
Chen, Didi
Ye, Yijia
Hu, Tingting
Li, Shiting
Hou, Meng
author_sort Zhuang, Lei
collection PubMed
description BACKGROUND: The chemotherapy drug doxorubicin (Dox) is widely used for treating a variety of cancers. However, its high cardiotoxicity hampered its clinical use. Exosomes derived from stem cells showed a therapeutic effect against Dox-induced cardiomyopathy (DIC). Previous studies reported that exosomes derived from mesenchymal stem cells (MSCs) pretreated with macrophage migration inhibitory factor (MIF) (exosome(MIF)) showed a cardioprotective effect through modulating long noncoding RNAs/microRNAs (lncRNAs/miRs). This study aimed to investigate the role of exosome(MIF) in the treatment of DIC. RESULTS: Exosomes were isolated from control MSCs (exosome) and MIF-pretreated MSCs (exosome(MIF)). Regulatory lncRNAs activated by MIF pretreatment were explored using genomics approaches. Fluorescence-labeled exosomes were tracked in vitro by fluorescence imaging. In vivo and in vitro, miR-221-3p mimic transfection enforced miR-221-3p overexpression, and senescence-associated β-galactosidase assay was applied to test cellular senescence. Exosomal delivering LncRNA-NEAT1 induced therapeutic effect in vivo was confirmed by echocardiography. It demonstrated that exosomes(MIF) recovered the cardiac function and exerted the anti-senescent effect through LncRNA–NEAT1 transfer against Dox. TargetScan and luciferase assay showed that miR-221-3p targeted the Sirt2 3′-untranslated region. Silencing LncRNA–NEAT1 in MSCs, miR-221-3p overexpression or Sirt2 silencing in cardiomyocytes decreased the exosome(MIF)-induced anti-senescent effect against Dox. CONCLUSIONS: The results indicated exosome(MIF) serving as a promising anti-senescent effector against Dox-induced cardiotoxicity through LncRNA–NEAT1 transfer, thus inhibiting miR-221-3p and leading to Sirt2 activation. The study proposed that exosome(MIF) might have the potential to serve as a cardioprotective therapeutic agent during cancer chemotherapy. [Image: see text]
format Online
Article
Text
id pubmed-7603694
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76036942020-11-02 Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p Zhuang, Lei Xia, Wenzheng Chen, Didi Ye, Yijia Hu, Tingting Li, Shiting Hou, Meng J Nanobiotechnology Research BACKGROUND: The chemotherapy drug doxorubicin (Dox) is widely used for treating a variety of cancers. However, its high cardiotoxicity hampered its clinical use. Exosomes derived from stem cells showed a therapeutic effect against Dox-induced cardiomyopathy (DIC). Previous studies reported that exosomes derived from mesenchymal stem cells (MSCs) pretreated with macrophage migration inhibitory factor (MIF) (exosome(MIF)) showed a cardioprotective effect through modulating long noncoding RNAs/microRNAs (lncRNAs/miRs). This study aimed to investigate the role of exosome(MIF) in the treatment of DIC. RESULTS: Exosomes were isolated from control MSCs (exosome) and MIF-pretreated MSCs (exosome(MIF)). Regulatory lncRNAs activated by MIF pretreatment were explored using genomics approaches. Fluorescence-labeled exosomes were tracked in vitro by fluorescence imaging. In vivo and in vitro, miR-221-3p mimic transfection enforced miR-221-3p overexpression, and senescence-associated β-galactosidase assay was applied to test cellular senescence. Exosomal delivering LncRNA-NEAT1 induced therapeutic effect in vivo was confirmed by echocardiography. It demonstrated that exosomes(MIF) recovered the cardiac function and exerted the anti-senescent effect through LncRNA–NEAT1 transfer against Dox. TargetScan and luciferase assay showed that miR-221-3p targeted the Sirt2 3′-untranslated region. Silencing LncRNA–NEAT1 in MSCs, miR-221-3p overexpression or Sirt2 silencing in cardiomyocytes decreased the exosome(MIF)-induced anti-senescent effect against Dox. CONCLUSIONS: The results indicated exosome(MIF) serving as a promising anti-senescent effector against Dox-induced cardiotoxicity through LncRNA–NEAT1 transfer, thus inhibiting miR-221-3p and leading to Sirt2 activation. The study proposed that exosome(MIF) might have the potential to serve as a cardioprotective therapeutic agent during cancer chemotherapy. [Image: see text] BioMed Central 2020-10-31 /pmc/articles/PMC7603694/ /pubmed/33129330 http://dx.doi.org/10.1186/s12951-020-00716-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhuang, Lei
Xia, Wenzheng
Chen, Didi
Ye, Yijia
Hu, Tingting
Li, Shiting
Hou, Meng
Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p
title Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p
title_full Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p
title_fullStr Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p
title_full_unstemmed Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p
title_short Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p
title_sort exosomal lncrna–neat1 derived from mif-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging mir-221-3p
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603694/
https://www.ncbi.nlm.nih.gov/pubmed/33129330
http://dx.doi.org/10.1186/s12951-020-00716-0
work_keys_str_mv AT zhuanglei exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p
AT xiawenzheng exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p
AT chendidi exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p
AT yeyijia exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p
AT hutingting exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p
AT lishiting exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p
AT houmeng exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p